Catalyst Pharmaceutical Partners Now Covered by Maxim Group (CPRX)
Stock analysts at Maxim Group began coverage on shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) in a report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $4.00 price target on the stock. Maxim Group’s price objective points to a potential upside of 39.37% from the stock’s previous close.
Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) opened at 2.87 on Tuesday. Catalyst Pharmaceutical Partners has a 52 week low of $0.37 and a 52 week high of $2.99. The stock’s 50-day moving average is $1.8 and its 200-day moving average is $1.09. The company’s market cap is $119.0 million.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last announced its earnings results on Thursday, August 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Analysts expect that Catalyst Pharmaceutical Partners will post $-0.25 EPS for the current fiscal year.
A number of other firms have also recently commented on CPRX. Analysts at Aegis raised their price target on shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) from $3.50 to $4.00 in a research note to investors on Friday, September 6th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “hold” rating on shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) in a research note to investors on Tuesday, August 27th. They now have a $1.00 price target on the stock.
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.